Geneuro
Develops therapies for neurological and autoimmune diseases by targeting HERVs.
GEM | PA
Overview
Corporate Details
- ISIN(s):
- CH0308403085
- LEI:
- 213800FUJCKXO9LK3444
- Country:
- Switzerland
- Address:
- chemin du Pré-Fleuri 3, 1228 Plan-les-Ouates
- Website:
- https://geneuro.ch/en/
Description
Geneuro is a clinical-stage biopharmaceutical company developing treatments for neurological and autoimmune diseases. The company's approach focuses on neutralizing pathogenic proteins expressed by human endogenous retroviruses (HERVs), which are believed to be causal factors in the progression of certain diseases. Its primary areas of development include conditions such as multiple sclerosis (MS) and post-COVID syndrome (long-COVID). Geneuro's lead product candidate, temelimab, is a monoclonal antibody designed to target and neutralize a specific HERV envelope protein. This strategy aims to block the inflammatory and neurodegenerative processes associated with these diseases, representing a precision medicine approach to treatment.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2023-12-11 08:00 |
Inside Information / Other news releases
|
English | PDF • 160.8 KB | ||
| 2023-11-28 08:00 |
Inside Information / Other news releases
|
English | PDF • 200.8 KB | ||
| 2023-11-28 08:00 |
Informations privilégiées / Autres communiqués
|
French | PDF • 169.9 KB | ||
| 2023-11-10 09:32 |
Franchissement de seuils
|
French | PDF • 201.0 KB | ||
| 2023-10-19 08:00 |
Inside Information / Other news releases
|
English | PDF • 187.1 KB | ||
| 2023-10-19 08:00 |
Informations privilégiées / Autres communiqués
|
French | PDF • 190.7 KB | ||
| 2023-10-06 15:59 |
Half yearly financial reports and audit reports/limited reviews / Half yearly f…
|
English | PDF • 1.6 MB | ||
| 2023-10-02 07:30 |
Informations privilégiées / Communiqué sur comptes, résultats
|
French | PDF • 269.0 KB | ||
| 2023-10-02 07:30 |
Inside Information / News release on accounts, results
|
English | PDF • 287.1 KB | ||
| 2023-09-27 07:30 |
Inside Information / Other news releases
|
English | PDF • 184.2 KB | ||
| 2023-09-27 07:30 |
Informations privilégiées / Autres communiqués
|
French | PDF • 99.2 KB | ||
| 2023-09-11 07:30 |
Inside Information / Other news releases
|
English | PDF • 283.4 KB | ||
| 2023-09-11 07:30 |
Informations privilégiées / Autres communiqués
|
French | PDF • 274.9 KB | ||
| 2023-07-25 18:00 |
Inside Information / Other news releases
|
English | PDF • 222.0 KB | ||
| 2023-07-25 18:00 |
Informations privilégiées / Autres communiqués
|
French | PDF • 221.5 KB |
Automate Your Workflow. Get a real-time feed of all Geneuro filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Geneuro
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Geneuro via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
